Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity.
نویسندگان
چکیده
Tacrolimus is widely used for immunosuppressant therapy, including various organ transplantations. One of its main side effects is hyperglycemia due to reduced insulin secretion, but the mechanism remains unknown. We have investigated the metabolic effects of tacrolimus on insulin secretion at a concentration that does not influence insulin content. Twenty-four-hour exposure to 3 nM tacrolimus reduced high glucose (16.7 mM)-induced insulin secretion (control 2.14 +/- 0.08 vs. tacrolimus 1.75 +/- 0.02 ng.islet(-1).30 min(-1), P < 0.01) without affecting insulin content. In dynamic experiments, insulin secretion and NAD(P)H fluorescence during a 20-min period after 10 min of high-glucose exposure were reduced in tacrolimus-treated islets. ATP content and glucose utilization of tacrolimus-treated islets in the presence of 16.7 mM glucose were less than in control (ATP content: control 9.69 +/- 0.99 vs. tacrolimus 6.52 +/- 0.40 pmol/islet, P < 0.01; glucose utilization: control 103.8 +/- 6.9 vs. tacrolimus 74.4 +/- 5.1 pmol.islet(-1).90 min(-1), P < 0.01). However, insulin release from tacrolimus-treated islets was similar to that from control islets in the presence of 16.7 mM alpha-ketoisocaproate, a mitochondrial fuel. Glucokinase activity, which determines glycolytic velocity, was reduced by tacrolimus treatment (control 65.3 +/- 3.4 vs. tacrolimus 49.9 +/- 2.8 pmol.islet(-1).60 min(-1), P < 0.01), whereas hexokinase activity was not affected. These results indicate that glucose-stimulated insulin release is decreased by chronic exposure to tacrolimus due to reduced ATP production and glycolysis derived from reduced glucokinase activity.
منابع مشابه
بررسی اثر گلیبنکلامید بر ترشح انسولین و فعالیت گلوکوکیناز در جزایر لانگرهانس پانکراس موشهای صحرایی سالم و دیابتی
Background: Sulfonylurea agents such as Glibenclamide (Glyburide) have been widely prescribe in treatment of type 2 diabetic patients for decades, but controversy remains about their precise mechanism of action. On the other hand, glucokinase serves as a glucose sensor in pancreatic β-cells and plays a key role in the regulation of insulin secretion and glucose homeostasis. The aim of the pres...
متن کاملبررسی اثر گلوکزآمین بر فعالیت آنزیمهای گلوکوکیناز و هگزوکیناز پانکراس و ارتباط آن با ترشح انسولین از جزایر لانگرهانس موشهای صحرایی سالم و دیابتی نوع 2
Background: Glucokinase serves as a glucose sensor in pancreatic β-cells and plays a key role in glucose homeostasis and glucose-stimulated insulin secretion (GSIS). In the present study we examined the effect of glucosamine, a glucokinase inhibitor, on the pancreatic glucokinase and hexokinase activities and on insulin secretion from freshly rat pancreatic islets of Langerhans. Insulin concen...
متن کاملبررسی اثر کاتیونهای فلزی V5+, W6+ , Zn2+ بر میزان ترشح انسولین و فعالیت آنزیم گلوکوکیناز در جزایر لانگرهانس جدا شده از موش صحرایی سالم و دیابتی
Background: Insulin dependant Diabetes Mellitus (IDDM) is associated with a reduction in production or secretion of insulin from pancreatic Islets. On the other hand increase in insulin secretion will result in destruction of islets that will lead to Diabetes .Therefore the factors that could regulate secretion will prevent the onset of diabetes . Glucose metabolism that commences with the gluc...
متن کاملEffect of Ganoderma lucidum hydroalcoholic extract on insulin release in rat-isolated pancreatic islets
Objective: Ganoderma Lucidum (G. Lucidum) has been suggested to increase serum insulin level.This study was undertaken to investigateits direct effect on the islets of Langerhans. Material and Methods: Male albino Wistar rats were anesthetized and the islets were isolated after digestion of the pancreas with collagenase. The islets were incubated for 60 min in Krebs bicarbonate buffer containi...
متن کاملDiphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets.
Diphenylhydantoin (DPH), which is clinically used in the treatment of epilepsy, inhibits glucose-induced insulin release from pancreatic islets by a mechanism that remains unknown. In the present study, DPH is shown to suppress glucose-induced insulin release concentration-dependently. In dynamic experiments, 20 microm DPH suppressed 16.7 mm glucose-induced biphasic insulin release. DPH also su...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- American journal of physiology. Endocrinology and metabolism
دوره 288 2 شماره
صفحات -
تاریخ انتشار 2005